

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GRLS | Derived | EUR | Real-time | |
GRLS | Madrid | EUR | Delayed | |
GRLSbn | Madrid | EUR | Delayed | |
GRFe | BATS Europe | EUR | Delayed | |
GRFPe | BATS Europe | EUR | Delayed | |
GRFS | NASDAQ | USD | Real-time | |
GIKLY | OTC Markets | USD | Delayed | |
0RDU | London | EUR | Real-time | |
0RDV | London | EUR | Real-time | |
GRFPN | Mexico | MXN | Delayed | |
1GRF | Milan | EUR | Real-time | |
GRLS | Vienna | EUR | Real-time |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify – CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Name | Age | Since | Title |
---|---|---|---|
Darcy Antonellis | 61 | 2023 | Non-Executive Director |
Juan Ignacio Twose Roura | 79 | 1973 | Member of the Advisory Committee |
Tomas Daga Gelabert | 69 | 2000 | Independent External Director |
Iñigo Sánchez-Asiaín Mardones | 61 | 2015 | Independent Director |
Albert Grifols Coma-Cros | 46 | 2023 | Proprietary Director |
Enriqueta Felip Font | 60 | 2019 | Independent Director |
Raimon Grifols Roura | 61 | 2001 | Vice-Chairman |
Thomas H. Glanzmann | 67 | 2006 | Non-Executive Chairman |
Susana Gonzalez Rodriguez | 48 | 2022 | Independent Director |
Anne-Catherine Berner | - | 2024 | Independent Director |
Pascal Ravery | - | 2024 | Independent Director |
Montserrat Muñoz Abellana | 56 | 2022 | Lead Independent Director |
Paul S. Herendeen | 69 | 2024 | Proprietary Director |
Víctor Grifols Deu | 48 | 2016 | Executive Director |
Jose Ignacio Abia Buenache | 57 | 2024 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review